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Abstract: Aerobic exercise, in spite of its multi-organ benefit and potent effect on the 
metabolome, has yet to be investigated comprehensively via an untargeted metabolomics 
technology. We conducted an exploratory untargeted liquid chromatography mass spectrometry 
study to investigate the effects of a one-h aerobic exercise session in the urine of three 
physically active males. Individual urine samples were collected over a 37-h protocol (two 
pre-exercise and eight post-exercise). Raw data were subjected to a variety of normalization 
techniques, with the most effective measure dividing each metabolite by the sum response 
of that metabolite for each individual across the 37-h protocol expressed as a percentage. 
This allowed the metabolite responses to be plotted on a normalised scale. Our results 
highlight significant metabolites located in the following systems: purine pathway, 
tryptophan metabolism, carnitine metabolism, cortisol metabolism, androgen metabolism, 
amino acid oxidation, as well as metabolites from the gastrointestinal microbiome. Many of 
the significant changes observed in our pilot investigation mirror previous research studies, 
of various methodological designs, published within the last 15 years, although they have 
never been reported at the same time in a single study.  
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1. Introduction 
From the smell and colour of urine as a tool for disease diagnosis [1] to the elusive promise of an 
³H[HUFLVHSLOO´DVDSUHYHQWDWLYHPHDVXUHRIGLVHDVH[2,3], could this be the future of health prescription? 
How could exercise, with its multi-factorial and multi-organ health benefits [2,4±7], be successfully 
administrated as an oral medication? If this theoretical pill existed, it would have to replicate the 
downstream metabolic effects of a single type of exercise tailored specifically to each unique 
metabolome or even metabotype [8,9]. Exercise, as an external challenge to the human metabolome, 
creates an immediate response (turn-over rate in seconds [10]) across this biological matrix, which, 
unlike studies investigating the effects of fasting, have been shown to exhibit large inter-subject 
variability [8,11]. Therefore, the question of dosing specific exercise regimes to varying population 
cohorts (sedentary vs. regularly active vs. athletes) in order to maximize the efficacy of the intervention 
remains to be answered. Therefore, how can we, by utilising evidence-based markers, predict the intensity 
and training modality that would ensure a quicker adaptation and improved outcome in these subgroups? 
The answer could lie within the plethora of human metabolism, which, in spite of its vast number of 
constituents, still is the most sensitive measure to investigate cellular and human phenotype [1,9,10].  
As such, metabolomics, the rapidly developing omics technology, allows for hundreds of metabolites 
(generally with a mass <'DDWSSPPDVVGHYLDWLRQWREHLQYHVWLJDWHGZLWKLQHDFKPHWDERORPH
at any given time-frame, FUHDWLQJDµVQDSVKRW¶RIWKHELRORJLFDOVWDWHRIDQRUJDQLVP [12]. A number of 
metabolomics-based studies have provided evidence to suggest that there is a clear effect of exercise on 
the human metabolome [4,13±15]. The most persistent observations concern effects on the purine 
pathway, highlighting increases in adenine nucleotides (AdN) in both acute and prolonged exercise 
regimes [16±23], with reduced excretion exhibited following an adaptative response [23] that is 
accommodated by a reduced level of resting hypoxanthine [17,22,24±27]. Moreover, Hellsten et al. [28] 
showed that muscle urate, as well as allantoin levels, the latter being a product of urate oxidation, were 
increased in habitually active male subjects following exhaustive exercise. Allantoin can only be formed 
non-enzymatically in humans, and it was concluded that uric acid was acting as an antioxidant against 
reactive oxygen species (ROS) generated during exercise. Hence, this could be a useful tool in examining 
levels of oxidative stress. As previously mentioned, plasma levels of hypoxanthine were also increased 
after exercise, and this may result from xanthine dehydrogenase being a rate limiting enzyme in urate 
formation [24]. In muscle, ATP is degraded to hypoxanthine, which is lost from the muscle, but may be 
salvaged by hypoxanthine-guanine phosphoribosyl transferase. Several papers have observed that 
hypoxanthine salvage tends to be more efficient in trained individuals and that, along with other purine 
metabolites, can provide an indication of the effectiveness of a training regime [26]. A targeted 
metabolomics study examining approximately 200 plasma metabolites in relation to exercise in 
individuals from a longitudinal cohort study concluded that metabolic profiles obtained during exercise 
gave a signature of exercise performance, as well as cardiovascular disease susceptibility [5]. Important 
marker metabolites for the effect of exercise included purine metabolites, tryptophan metabolites, 
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citrulline (marker of nitric oxide formation and present to a lesser extent in the plasma of fitter 
individuals) and, finally, nicotinamide (tryptophan metabolite), which is known to enhance insulin  
release [5]. Lustgarten et al. [29] noted a positive correlation between maximum oxygen consumption 
( ሶܸO2max) with tryptophan, and an increase in tryptophan-related metabolites, such as kynurenate, was 
exhibited in a study of individuals after running the 26.2-mile Boston marathon. A 1H-NMR investigation 
into same sex twins looked into the effect of prolonged physical activity adherence to metabolic and 
gene expression links [4]. Numerous differences were found between persistently physically active and 
inactive individuals in the circulating metabolome, and the results reflected better cardio-metabolic 
health in the physically active twin [4]. 
Apart from the aforementioned studies, there have been very few comprehensive liquid chromatography 
mass spectrometry (LC-MS)-based investigations utilising an untargeted metabolomics method. The 
research conducted by Lewis et al. [5] and the Nieman et al. [13,30] on the effects of exercise have set 
a standard for future work; however, there are new prospects available in metabolite coverage and 
understanding due to the rise of high resolution and high throughput monitoring systems. Therefore, we 
conducted an exploratory, hypothesis generating pilot study utilising an untargeted LC-MS method in 
order to explore the effects of a one-h aerobic exercise challenge in the urine metabolome of three 
physically active males. We utilised our well-established hydrophilic interaction chromatography 
(HILIC) method to carry out the analysis [30±32]. The use of urine provides an ideal non-invasive 
method that results in a large overview of the metabolite matrix. As serialised time points, each 
individual urine sample provides an averaged response of the metabolic output of a particular individual 
and, in doing so, provides a unique overview of the daily metabolite variation. Hence, we devised a 
continuous 37-h protocol with sampling pre- and post-exercise accounting for the majority of the time-
points (across 31 h) in order to generate an understanding of the acute effects of exercise and, where 
possible, the duration of that response in the metabolite profiles.  
2. Materials and Methods 
2.1. Ethics Statement (UEC 14/28, Watson/Daskalaki: Pilot Exercise Trial) 
This study was approved by the Ethics Committee of the University of Strathclyde (Glasgow, UK) 
and conformed to the Declaration of Helsinki. Prior to successful recruitment, all subjects completed a 
physical activity readiness questionnaire, as well as a health questionnaire, in order to assess physical 
activity levels and to ensure that they had no history of the following: anaemia, diabetes, epilepsy, as 
well as any underlying respiratory or cardiovascular complications. All subjects gave written informed 
consent to participate. 
2.2. Subjects and Experimental Design 
Three physically active, non-smoking males (age range: 32±38 years) participated in the pilot study. 
The subjects were regularly engaged in predominantly running, long-distance walking and cycling. For 
at least two weeks prior to study commencement, subjects were asked to abstain from taking any sport 
or nutritional supplements and had no sign of illness. Subjects underwent a two-day (37 hour) trial, 
whereby urine samples were collected at regular intervals across this timeline: Day 1, ~08:00  
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Pre-exercise (P) 1 , first pass urine), 11:00 (P2), 14:00 (Post-exercise (PT) 1 17:00 (PT2) and 21:00 
(PT3); and Day 2, ~8:00 (PT4; first pass urine), 12:00 (PT5), 14:00 (PT6), 17:00 (PT7) and 21:00 (PT8)). 
Aerobic exercise was performed at the Strathclyde Sport and Recreational Centre (Glasgow, U.K.) on 
Day 1 between 12:00 and 13:00 (referred to as the A.E. session in this diagram) on either a treadmill, 
bicycle ergometer or in a combination. Subjects were permitted to control their own pace and drink water 
ad libitum, but had to be engaged in activity for at least 50 min. After the exercise session and for the 
remainder of the sample collection timeline, subjects were asked to refrain from any physical activity. 
Figure 1 provides a full illustration of the two-day protocol. 
 
Figure 1. Illustration of experimental design and sample collection. 
2.3. Sample Collection and Preparation  
Coded, pre-labelled sterilised urine containers were distributed to the subjects along with cool bags 
(Sistema Plastics, available from Amazon Co., Slough, UK) for storage and transport to the laboratory 
located at the Strathclyde Institute of Pharmacy and Biomedical Sciences. A designated drop-off section 
(at a temperature of í35 °C) was created for the samples. The unopened urine containers were stored for 
a maximum of two weeks prior to being thawed at room temperature and prepared for LC-MS analysis. 
For the analysis , using a ZIC-pHILIC column, 200 ȝ/ of urine were thoroughly mixed with 800 ȝ/ of 
ACN, followed by centrifugation at 7840 relative centrifugal force for 5 min; 800 ȝ/ of supernatant 
were then transferred to an LC auto-sampler vial (Thermo Fisher, UK). For quality control purposes, a 
pooled sample representing all subjects, as well as a subject-specific pooled sample were prepared (the 
latter utilised as a normalisation technique). For the pooled samples, 100 ȝ/ of urine were gathered from 
each sample and then treated as above. Four standard mixtures containing 150 authentic standards were 
run also after the samples. 
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2.4. Measurement of Creatinine  
Fifty microlitres of diluted samples and prepared creatinine standard stock solutions were thoroughly 
mixed with 100 ȝ/ of creatinine detection reagent (Enzo Life Sciences, Exeter, UK) in a 96-well plate. 
Absorbance was read at 490 nm via a Spectra Max M5 from Molecular Devices. The concentrations of 
creatinine in the test samples were calculated as stated previously in the literature [31]. 
2.5. Chemicals and Solvents 
HPLC-grade acetonitrile (ACN) was purchased from Fisher Scientific, U.K., and HPLC-grade water 
was produced by a Direct-Q 3 Ultrapure Water System (Millipore, U.K.). AnalaR-grade formic acid 
(98%) was obtained from BDH-Merck (Poole, Dorset, U.K.). Authentic stock standards were prepared 
as stated previously in the literature [30] and diluted 4 times with ACN before LC-MS analysis. 
Ammonium carbonate was purchased from Sigma-Aldrich, U.K. 
2.6. LC-MS Method 
LC-MS data were acquired on an Accela HPLC (Thermo Fisher Scientific) coupled to an Exactive 
Orbitrap (Thermo Fisher Scientific, Hemel Hempstead, UK) in both positive and negative mode set at 
50,000 resolution (controlled by Xcalibur version 2.1.0; Thermo Fisher Corporation, Hemel Hempstead, 
UK). The mass scanning range was m/z 75±1200; the capillary temperature was 320 °C; and the sheath 
and auxiliary gas flow rates were 50 and 17 arbitrary units, respectively. The separation was performed 
on a ZIC-pHILIC column (150 × PPȝPIURP+L&KURP, Reading, UK) in binary gradient mode. 
The mobile phase used was 20 mM ammonium carbonate buffer (pH 9.2) and pure ACN; the flow rate 
was 300 ȝ/·miní1. The gradient was programed as follows: 0 min 20% A/80% B to time 30 min 80% 
A/20% B. The injection volume was 10 ȝ/, and the sample tray temperature was controlled at 12 °C 
during the measurement. Samples were run in a stratified method with between-subject samples placed 
in randomised order. 
2.7. LC-MS Data Processing with MzMatch and Ideom (Version 19) 
Raw LC-MS files were converted to mzXML (ProteoWizard) and separated into ESI positive and 
negative. Converted files were then processed with open source MzMatch (http://mzmatch.sourceforge.net/) 
and the identification of putative metabolites was made via the macro-enabled Excel file, Ideom 
(http://mzmatch.sourceforge.net/ideom.html). Details regarding the data processing, metabolite 
identification, as well as databases available through Ideom can be found in previous literature [33]. 
Details of the R script for data processing with MzMatch and Ideom configurations can be found in 
supplementary File S1, R script, and Table S1, Ideom settings, respectively. 
2.8. Statistical Analysis  
Graphical representations, tabular features and statistical analysis (p-value generation) were 
performed in Excel (Microsoft Office 2013). Raw data were subjected to a variety of normalisation 
techniques; pooled subject-specific MS creatinine samples, MS and spectrophotometric creatinine, as 
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well as a subject-specific area percentage. For the latter, the first step includes calculating the sum of the 
peak areas of each metabolite across the 37-h protocol for each subject individually. Secondly, each 
respective metabolite response from every time point is then divided by the subject specific sum and 
multiplied by 100. Paired t-tests and fold changes were calculated on the new area percentage dataset. 
In order to observe the effect of the various normalisation strategies, data were also subjected to 
unsupervised PCA (scaled to unit variance) via SIMCA-P 13 (Umetrics, Sweden).  
3. Results  
Normalisation 
Since the strength of urine can vary, a major question in urinary metabolomics is how does one 
normalise to allow for variation in strength? Creatinine normalisation is often used, yet the reliability of 
such a method is uncertain; this is, in fact, discussed at length in the review on urinary normalization 
techniques by Ryan et al. [34]. It is clear from a number of metabolomics studies examining differences 
between individuals that each person presents a unique metabolic profile [8,11]. These inter-individual 
variations can be seen between the clustering patterns of the principal component analysis (PCA), where 
data have been normalised to either: (1) MS creatinine; (2) pooled subject-specific MS creatinine; or  
(3) spectrophotometric creatinine (Figure 2). The result of normalising to MS response for creatinine  
(Figure 2a) does not vary from the original raw dataset and does not improve the observed clustering 
between the subjects. However, when attempting to normalise to pooled subject-specific (Figure 2b) and 
spectrophotometric (Figure 2c) creatinine, the results vary considerably, especially for the latter. Having 
previously seen the clustering of each subject uniquely, the results of normalisation via the assay kit aid 
in the potential further differentiation of two metabotypes within our results. In Figure 2c, all of  
Subject 3¶V samples are separated from Subjects 1 and 2. Given that all our subjects were healthy, non-
smoking and regularly active, this could be an additional factor in determining relative fitness prior to 
any form of exercise challenge due to the relationship of creatinine clearance and muscle activity. The 
most effective strategy, however, can be seen in Figure 1d, as the data are normalised to the  
subject-specific area percentage. This approach has not been widely used, but there is some justification 
for doing this, as an almost complete recording for each metabolite was collected over the designated 
time-frame of the study. There are very few studies that have collected urine samples separately over 
long periods, so there is no information variability of individual metabolites with time. Table 1 shows a 
range of metabolites in urine with their relative standard deviation (RSD) over 30 samples taken from 
our three subjects. Many of the amino acids have only small variations over time, indicating that they 
are sufficiently abundant in the body. However, this may suggest that they are not affected to such a 
great extent by this particular form of exercise; ultimately, maintaining a relatively constant output. On 
the other hand, there are some metabolites shown in Table 1 that are very variable over time.  
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Figure 2. Normalisation strategies applied to the urine metabolome of three subjects  
(~1,000 putative metabolites). PCA of data normalised to: (a) the MS creatinine value of 
each unique sample detected exhibiting a similar pattern to raw data (R2X: 0.721; 
Q2: 0.432); (b) the MS creatinine value of subject-specific pooled samples (i.e., pooled 
Subject 1 creatinine value utilised to normalise all of Subject 1¶V raw data, and so on;  
R2X: 0.767; Q2: 0.489); (c) spectrophotometric creatinine value (the normalised data are 
closely clustered in the PCA model with the exception of all sampling time-points from 
Subject 3; R2X: 0.883; Q2: 0.468); and (d) subject-specific area percentage (R2X: 0.704; 
Q2: 0.447; showing the smallest difference between the goodness of fit and predicted fit). 
The PRE group includes Pre 1 (P1) and P2; the POST1 group includes Post 1 (PT1), 2  
and 3; POST2 includes PT4, 5, 6, 7 and 8.  
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Table 1. RSD values for metabolites across 30 urine samples collected over 37 hours.  
Compound Mass Retention Time (RT) (min) RSD (%) 
* Creatinine 113.050 10.1 16.3 
* Threonine 119.058 14.9 25.4 
Imidazolone propanoate 156.053 11.5 25.5 
* Glutamine 146.069 15.5 27.2 
* Serine 105.043 16.1 27.7 
Dihydrothymine 128.058 15.2 31.2 
N-acetylhistidine 197.080 10.6 31.5 
Dimethylarginine 202.143 22.0 31.9 
Dihydrouridine 246.085 10.8 32.0 
* Betaine 117.079 11.7 32.3 
* N-acetylglucosamine 221.090 12.2 33.2 
N-acetylarginine 216.122 15.3 34.9 
* N6-acetyllysine 188.116 15.5 35.6 
* Adenine 135.055 9.5 37.9 
* Methylthioadenosine 297.089 7.0 38.1 
* Citrulline 175.096 15.9 39.0 
* Proline 115.063 13.2 40.0 
Methylimidazole acetic acid 140.058 9.7 41.0 
* Alanine 89.048 15.2 41.3 
* Methylhistidine 169.085 13.3 41.9 
Thymine 126.043 12.0 42.3 
* Isoleucine 131.095 11.6 42.5 
Butenyl carnitine 229.131 9.8 42.8 
Methylcytosine 125.059 11.0 43.2 
* N-acetylglutamine 188.080 11.0 44.2 
* Adenosine 267.097 9.3 44.9 
* Phenylalanine 165.079 10.5 46.8 
* Histidine 155.069 15.0 47.9 
* Kynurenine 208.085 11.2 51.2 
* Cytosine 111.043 11.6 51.1 
* Ornithine 132.090 22.3 56.6 
* Tryptophan 204.090 12.0 55.6 
Carnitine 161.105 13.8 60.4 
* Arginine 174.112 26.4 62.6 
Creatinine (assay kit) - - 73.0 
* Pantothenate 219.111 8.9 82.4 
Tetrahydro aldosterone glucuronide 542.273 7.4 84.8 
* Lysine 146.105 25.0 100.6 
* Pyruvate 88.016 8.3 106.3 
Cresol glucuronide 284.090 7.8 113.1 
* Urate 168.028 13.0 121.6 
* Xanthosine 284.075 12.7 141.3 
* Tyrosine 181.074 13.3 133.7 
Metabolites 2015, 5 127 
 
 
Table 1. Cont. 
Compound Mass Retention Time (RT) (min) RSD (%) 
* Inosine 268.081 11.2 180.3 
* Hypoxanthine 136.038 10.5 186.1 
Deoxyinosine 252.086 9.0 210.6 
* Matches the retention time of an authentic standard. 
Figure 3 shows the variation in MS creatinine compared to some other metabolites (phenylalanine, 
carnitine, threonine, glutamine and stachydrine) that do not change very much over time for the three 
subjects; whereas, in Figure 4, variations in metabolites of the purine pathway (hypoxanthine, xanthosine, 
inosine and guanine) are shown in comparison to MS creatinine. As exhibited in Table 1, there are large 
variations across variable, as well as non-variable metabolites, and Figure 3 further emphasises that 
creatinine does not, in fact, follow a similar pattern to other metabolite markers. It is obvious from the 
similar trend response across the three subjects that the purines reflect a very strong acute impact of 
exercise; with peak levels observed at the first post-exercise sample (PT1). They also exhibit fluctuations 
over a smaller range on the following day. These metabolites are all in the pathway for ATP catabolism. 
The levels of adenosine (RSD in Table 1) were not affected to the same extent by exercise as the other 
purines, and thus, the breakdown of ATP appears not to proceed via this branch of the purine metabolism 
pathway. The effects of exercise and purine catabolism have been extensively described in the  
literature [20±28], and in particular, hypoxanthine has been the most studied of the purines. 
 
Figure 3. Comparison of the exercise response of the area percentage for MS creatinine 
(orange) with phenylalanine (red), carnitine (purple), threonine (green), glutamine (dark 
blue) and the dietary xenobiotic stachydrine (light blue). 
Figure 4 shows the effects of exercise on four metabolites in the purine pathway in the three subjects. 
The four purines, hypoxanthine, inosine, xanthosine and guanine, fluctuate in a very similar manner and 
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are all high in PT1; they also exhibit fluctuation over a smaller range on the following day. These 
metabolites are all in the pathway for ATP catabolism. The levels of adenosine (RSD in Table 1) were 
not affected to the same extent by exercise as the other purines, and thus, the breakdown of ATP appears 
not to proceed via this branch of the purine metabolism pathway. Effects on purine catabolism have been 
extensively described in the literature [20±28]. 
 
Figure 4. Comparison of the exercise response of the area percentage for MS creatinine 
(orange) with the levels of some metabolites from the purine pathway, hypoxanthine (light 
blue), xanthosine (green), inosine (red) and guanine (purple). 
The possible permutations for comparison of the ten sampling points are large, so in order to investigate 
the impact of exercise on the wider metabolome, the first post-exercise sample was taken as the best to 
reflect the impact of exercise according to the previously established effect on purine metabolism. 
Hence, statistical analysis was carried out with the first post-exercise sample as the reference point in 
order to observe the metabolites that were most immediately impacted by exercise (Table 2). This would 
additionally provide a possible time series analysis in order to determine how long it took for the effect 
of the exercise intervention to subside. This adds statistical power, despite the small sample size, since 
nine points for each person can be referenced to the first post-exercise sample (PT1). Table 2 summarises 
the metabolites that were most significantly changed between the P1 and PT1 points. Having established 
the most significant changes between these two points, subsequent differences between PT1 and some 
of the other post-exercise points (PT2, 4, 5 and 7) were added to the table. Some of the metabolites 
affected by exercise took over 24 h to return to the level of the first pre-point. Comparison with the 
second pre-point (P2) did not produce as distinct differences for certain metabolites as can be seen in the 
comparison between PT1 and P1. This is probably due to the fact that the physical activity of the subjects 
(mainly in the morning travel methods of the subjects) prior to the exercise session was not strictly 
controlled. However, in many cases, there were still significant differences between P2 and PT1. 
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Table 2. Normalised urinary metabolites which are significantly changed by exercise for three subjects. P-value and ratio change for 
comparisons PT1 (first post-exercise sample) vs. P1 (pre 1), P2 (pre 2), PT4 (post 4), PT5 (post 6), PT5 (post 7) and PT7 (post 7). The majority 
of the metabolites match metabolites in the human metabolome to within 2 ppm and thus are characterised to MSI level 2 where alternative 
metabolites could be isomers of the identity assigned.  
 Mass 
RT 
(min) 
PT1/P1 PT1/P2 PT1/PT2 PT1/PT4 PT1/PT5 PT1/PT7 
Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value 
Purine metabolism               
N2-N2-Dimethylguanosine 311.123 9.0 2.59 0.0200 1.57 0.11 1.97 0.12 1.18 0.61 2.68 0.070 4.75 0.0043 
Xanthosine * 284.075 12.7 16.18 0.0191 8.24 0.019 3.98 0.014 5.25 0.022 13.7 0.017 18.6 0.019 
Inosine * 268.081 11.2 581 0.045 10.8 0.048 5.55 0.049 5.64 0.0591 12.14 0.045 88.8 0.046 
Deoxyinosine 252.086 9.0 43.3 0.010 15.6 0.0091 11.9 0.0060 8.87 0.0037 25.13 0.0062 53.4 0.0093 
Guanine * 151.049 12.7 5.01 <0.001 4.17 0.0017 33.7 <0.001 3.30 <0.001 10.17 <0.001 27.7 <0.001 
Hypoxanthine * 136.038 10.5 22.8 0.025 11.0 0.026 9.86 0.023 6.96 0.016 15.5 0.020 27.3 0.023 
Kynurenine pathway               
** 3-Hydroxytryptophan 220.085 10.3 2.69 0.012 1.45 0.12 1.52 0.27 0.93 0.83 2.14 0.095 3.66 0.0095 
 Xanthurenic acid isomer 205.037 11.3 4.55 0.0023 1.93 0.0072 1.95 0.085 1.76 0.15 2.14 0.044 3.91 0.0001 
Kynurenate 189.043 6.6 3.36 0.085 2.71 0.13 1.57 0.42 1.59 0.31 2.55 0.13 3.87 0.092 
Hydroxytryptophol 177.079 7.5 3.74 0.0048 0.98 0.97 1.86 0.14 2.22 0.016 2.43 0.026 4.01 0.0040 
N1-Methyl-2-pyridone-5-carboxamide 152.059 7.8 2.27 0.042 1.56 0.40 1.28 0.58 0.86 0.68 1.44 0.44 3.12 0.0012 
Glycolysis               
Pyruvate * 88.016 8.3 6.79 0.026 5.93 0.02 2.11 0.12 2.81 0.041 9.08 0.024 6.50 0.031 
Methyl oxalate 118.027 8.5 3.09 0.011 1.68 0.31 0.95 0.92 1.14 0.82 1.96 0.13 3.12 0.0026 
Vitamins               
Riboflavin * 376.138 8.9 3.01 0.047 1.19 0.59 2.63 0.055 0.75 0.50 2.92 0.043 8.94 <0.001 
Pantothenate * 219.111 8.9 5.09 0.031 3.18 0.048 1.96 0.13 2.19 0.071 3.44 0.034 4.37 0.042 
Neurotransmitter metabolism               
L-Metanephrine * 197.105 18.6 4.56 0.013 2.00 0.050 1.88 0.13 1.45 0.42 2.90 0.035 5.21 0.026 
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Table 2. Cont. 
 Mass 
RT 
(min) 
PT1/P1 PT1/P2 PT1/PT2 PT1/PT4 PT1/PT5 PT1/PT7 
Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value 
Microbial metabolism               
Indole-3-acetyl-glutamine 303.122 8.2 4.86 0.010 1.61 0.26 3.36 0.024 1.38 0.28 3.64 0.021 8.02 0.011 
5-Hydroxyindolepyruvate 219.053 5.3 3.99 0.0045 1.90 0.036 1.92 0.13 1.30 0.46 2.54 0.082 3.35 0.0067 
Indoxyl sulphate 213.010 7.4 3.07 0.050 2.05 0.19 2.23 0.1155 1.48 0.4326 3.62 0.044 11.57 0.040 
Hydroxyferulate 210.053 6.8 3.81 0.042 2.83 0.084 1.36 0.5378 1.55 0.27 6.27 0.040 5.87 0.044 
Cresol sulphate 187.008 4.5 2.97 0.037 1.37 0.34 2.14 0.13 0.96 0.91 3.48 0.029 4.05 0.026 
Phenol sulphate 173.999 5.0 3.32 0.0042 2.02 0.17 1.84 0.15 1.01 0.99 2.13 0.075 3.83 0.0034 
Urocanate 138.043 7.5 2.81 0.054 2.03 0.036 1.73 0.16 2.02 0.049 2.97 0.027 5.50 0.014 
Amino acids               
Tryptophan * 204.090 12.0 2.02 0.044 0.90 0.62 1.24 0.58 0.77 0.60 1.49 0.32 2.36 <0.001 
O-Acetyl-L-homoserine 161.069 8.6 3.76 0.019 2.91 0.047 1.54 0.42 1.75 0.1177 3.06 0.023 4.23 0.019 
Histidine * 155.069 15.0 0.41 0.047 0.39 0.073 0.67 0.44 0.62 0.30 0.29 <0.001 0.34 0.019 
D-Methionine * 149.051 7.6 2.40 0.017 1.32 0.16 1.51 0.27 1.11 0.70 1.78 0.21 1.98 0.015 
L-Proline * 115.063 13.2 3.88 0.018 1.85 0.091 2.18 0.058 1.74 0.12 2.38 0.047 3.53 0.035 
Amino acid metabolism               
N-Acetylvanilalanine 253.095 8.0 7.48 0.0020 3.19 0.035 2.28 0.15 2.52 0.085 4.18 0.018 7.21 < 0.001 
N-(Carboxyethyl) arginine 246.133 14.6 5.16 0.027 3.43 0.039 2.98 0.031 3.10 0.027 4.27 0.026 4.13 0.032 
N-Acetyl-D-tryptophan 246.101 6.6 3.60 0.051 3.28 0.047 1.29 0.68 1.45 0.25 2.47 0.087 5.42 0.055 
N-acetylmethionine 191.062 6.1 4.85 0.039 3.26 0.052 1.85 0.22 1.68 0.19 2.9 0.070 6.07 0.046 
Amino acid oxidation               
Indole pyruvate 203.059 6.9 2.36 0.030 1.59 0.40 1.14 0.81 1.44 0.46 3.07 0.025 3.39 0.014 
Acetamido-oxohexanoate 187.084 8.4 2.71 0.029 1.84 0.24 1.37 0.38 1.44 0.31 2.28 0.031 4.42 0.0075 
Hydroxyphenylpyruvate 180.042 7.9 4.43 0.0030 2.63 0.077 1.54 0.41 1.80 0.12 4.66 0.0032 4.94 0.0051 
Oxoarginine 173.080 14.7 1.99 0.04 1.78 0.089 1.96 0.052 1.63 0.078 2.88 0.018 2.18 0.045 
Guanidovaleramide 158.117 24.7 6.74 0.0015 2.33 0.032 1.61 0.37 1.33 0.65 3.42 0.080 9.27 0.0049 
Acetohydroxybutanoate 146.058 7.0 5.67 0.0016 3.51 0.0310 1.99 0.14 1.49 0.31 3.01 0.012 6.47 <0.001 
Acetamidobutanoate 145.074 7.1 3.17 0.0095 2.24 0.14 1.69 0.28 1.80 0.13 2.82 0.029 6.39 0.0069 
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Table 2. Cont. 
 Mass 
RT 
(min) 
PT1/P1 PT1/P2 PT1/PT2 PT1/PT4 PT1/PT5 PT1/PT7 
Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value Ratio p-Value 
Amino acid oxidation               
Dihydroxymethylbutanoate 134.058 9.2 8.00 0.030 3.23 0.053 1.74 0.32 0.79 0.74 1.31 0.58 2.54 0.10 
Methyl-oxopentanoic acid 130.063 5.2 4.21 0.026 2.65 0.068 1.51 0.45 1.18 0.66 2.32 0.084 3.68 0.030 
Dioxopentanoate 130.027 8.8 2.31 0.046 1.56 0.39 1.10 0.85 0.94 0.84 1.47 0.31 2.18 0.035 
Hydroxypentanoate 118.063 7.1 2.72 0.018 1.72 0.28 0.94 0.92 0.71 0.58 1.42 0.48 2.99 0.0035 
Methyloxobutanoic acid 116.047 6.9 3.12 0.013 1.95 0.19 1.25 0.70 0.85 0.78 1.46 0.48 3.60 0.0020 
Hydroxybutanoic acid 104.047 8.2 3.24 0.010 2.09 0.15 1.31 0.60 0.86 0.75 1.51 0.40 2.96 0.011 
Carnitine metabolism               
Dodecenoylcarnitine 341.256 5.5 4.59 0.0025 3.00 0.030 2.67 0.045 1.52 0.13 3.55 0.051 5.19 < 0.001 
Undecanoylcarnitine 329.256 5.5 3.08 0.026 1.57 0.20 1.48 0.35 1.32 0.40 2.07 0.17 3.83 0.028 
Decanoylcarnitine 315.241 5.8 3.07 0.045 2.00 0.065 1.71 0.24 1.18 0.66 2.40 0.1425 5.05 <0.001 
L-Octanoylcarnitine 287.209 6.4 2.15 0.016 1.41 0.19 1.52 0.31 0.71 0.51 1.46 0.47 3.18 0.004 
Methylglutarylcarnitine 261.121 5.6 1.92 0.078 2.08 0.18 1.24 0.58 0.60 0.23 2.10 0.023 2.06 0.013 
Hexanoylcarnitine 259.178 7.7 2.26 0.041 1.17 0.55 1.15 0.77 0.85 0.71 1.55 0.39 3.37 0.027 
Valerylcarnitine 245.162 10.7 2.33 0.0186 1.74 0.065 1.36 0.42 0.98 0.96 2.52 0.0082 2.91 0.0075 
Dehydroxycarnitine 145.110 15.8 2.76 0.0095 1.89 0.023 1.65 0.20 1.52 0.15 2.69 0.012 3.00 0.0082 
Steroid metabolism               
Urocortisol glucuronide 542.273 7.4 6.48 0.0036 2.68 0.062 1.84 0.16 2.16 0.063 2.60 0.045 5.84 0.011 
Dihydrocortisone glucuronide 540.257 5.5 5.47 0.029 2.59 0.082 3.70 0.028 2.04 0.075 3.65 0.032 8.43 0.033 
Hydrocortisone sulphate 442.166 4.3 8.83 0.060 3.13 0.084 5.16 0.060 2.74 0.092 5.40 0.051 25.26 0.055 
Hydroxyandrosterone glucuronide 482.252 5.5 4.27 0.0064 2.21 0.14 2.24 0.068 1.79 0.091 2.90 0.018 5.08 0.017 
Androstane diol glucuronide 468.272 5.6 2.77 0.0082 2.11 0.17 1.71 0.21 1.24 0.51 2.38 0.065 4.45 0.0029 
Androsterone glucuronide 466.257 4.8 3.59 0.0039 1.99 0.19 1.84 0.19 1.40 0.32 2.43 0.076 5.00 0.0069 
Oxoandrostane glucuronide 480.236 5.3 4.13 0.046 2.17 0.15 2.03 0.13 1.47 0.32 2.83 0.061 9.22 0.051 
* Metabolomics Standard Initiative Level 1: finding matches the retention time of the authentic standard; ** retention time earlier than the 5-hydroxytryptophan standard;  
 retention time later than the xanthurenic acid standard. 
Metabolites 2015, 5 132 
 
4. Discussion 
4.1. Tryptophan Metabolism 
In addition to the purine pathway, a number of other metabolite pathways were significantly affected 
by exercise. Lewis et al. [5] observed effects on the kynurenine pathway in response to exercise, and we 
observe the same type of effect in the current study with a weak effect on kynurenate and a clearer effect 
on 3-hydroxy tryptophan and hydroxyindole pyruvate, hydroxytryptophol, as well as pyridone 
carboxamide, which are also present in this pathway. Initially, we thought that xanthurenate  
(3-hydroxykynurenate) was also affected by exercise, but the affected compound shown in Table 2 
appears to be an isomer of xanthurenate. Effects on tryptophan metabolism following exercise were also 
observed by Lustgarten et al. [29]. There is an early report that kynurenate can be converted  
non-enzymatically into 6-hydroxykynurenate, and this may occur in urine when levels of kynurenate are 
high [35]. We have previously observed in the completely different metabolic system of Drosophila that 
inhibition of the purine metabolism pathway with allopurinol caused a fall in metabolism within the 
kynurenine pathway [36].  
4.2. Glycolysis 
Pyruvate is strongly elevated by exercise, and this would be expected as a result of increased  
reliance on glycolysis as the source of energy with the decreased entry of pyruvate into the Krebs cycle. 
Lewis et al. [5] observed increased levels of pantothenate in plasma taken from marathon runners, and 
we also observe a large increase. It was proposed that elevated pantothenate resulted from an increased 
demand for CoA biosynthesis [5], but in the current case, pantothenic acid is excreted, which might 
reflect a decreased demand for CoA. This could also reflect a switch to glycolysis in place of fat 
metabolism. It has been observed that fat metabolism decreases with an increasing exercise intensity, 
and there is an increase in reliance on glycogen to supply energy [37]. Fatty acid levels in plasma have 
been found to increase after exercise, and in the current case, possibly, this is reflected by the rapid fall 
in urinary pantothenic acid levels post-exercise. Furthermore, the urinary levels of the adrenaline 
metabolite, metanephrine, are elevated and do not decline to pre-exercise levels until nearly 24 h later. 
4.3. Microbiome Metabolites 
An unexpected and wide ranging effect of exercise is on the levels of microbial metabolites in urine. 
Five metabolites clearly associated with the gut microflora are moderately to highly elevated by exercise 
and include metabolites of tryptophan, such as the uremic toxin, indoxyl sulphate, indole pyruvate and 
hydroxyindole pyruvate [38], the tyrosine metabolites cresol sulphate and phenol sulphate [39], as well 
as the histamine, metabolite urocanic acid. Elevated levels of a number of other amino acid oxidation 
products are observed, and these may also result from microbial activity [40]. This could have important 
implications for physiological function during exercise when one considers that cresol sulphate and 
indoxyl sulphate are potent uremic toxins. Again, this effect has been previously observed by Lustgarten et al., 
highlighting increases in a range of products of gut microflora, including phenol sulphate, p-cresol sulphate, 
urocanic acid and 3-indoxyl sulphate in physically-impaired adults following an exercise programme [41].  
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4.4. Amino Acid Oxidation 
As shown in Table 2, there are many oxidation products of amino acids produced in response to 
exercise that are supported in previous studies. Lustgarten et al. [29] observed increases in  
Į-hydroxyisocaproate, indolelactate hydroxyisovalerate and 2-hydroxy-3-methylvalerate in their study 
of exercise in physically-impaired adults. They linked increases in these metabolites with PPAR-Į
activation. In our study, we have observed the keto acids to a greater extent than the corresponding 
hydroxyl acids, which is more in line with Pechlivanis et al., who observed increased oxidation of branch 
chain fatty acids in the urine of moderately trained males post-exercise (three sets of 80-m maximal runs 
separated by either 10 s or 1 min) [17]. 
4.5. Carnitines  
Another group of metabolites that are affected by exercise are fatty acid carnitine conjugates. In 
particular, we observed increases in C12:0, C10:0 and C8:0 carnitines, which have been reported 
previously [42]. Romijn et al. [43] showed that glucose inhibited the metabolism of palmitic acid during 
exercise. Glycolysis is increased during exercise since two molecules of ATP are generated during the 
conversion of glucose to pyruvate without the requirement of oxygen. Pyruvate then enters mitochondria 
and is converted to acetyl CoA, which produces one molecule of NADH, but this does not require 
investment of ATP. In contrast, coupling of a fatty acid to CoA requires one molecule of ATP and the 
FADH and NADH produced during a fatty acid oxidation step. This requires oxygen in order for them 
to be converted to ATP in the terminal respiratory chain. Thus, it would seem logical that further 
oxidation of pyruvate via the Krebs cycle might take precedence over fatty acid oxidation when ATP is 
at a premium. In order to enter mitochondria, fatty acids have to be converted into acyl carnitines, where 
they are then conjugated to CoA and undergo oxidation. Carnitine conjugation is also used to transport 
fatty acids out of mitochondria in order to ensure that sufficient levels of free CoA are maintained; this 
allows the Krebs cycle to function [44]. CoA is released once acetyl CoA enters the Krebs cycle, but is 
required once more in the formation of succinyl CoA. Thus, in order to maintain free CoA, fatty acids 
conjugated to CoA may be converted to acyl carnitines and be removed from mitochondria and, 
ultimately, excreted. Measurement of urinary acyl carnitine levels is used to diagnose in born errors of 
fatty acid metabolism, which result from a defect in one of the beta oxidation steps during fatty acid 
metabolism in the mitochondria. In such conditions, in order to preserve free levels of CoA, the partly 
metabolised fatty acid is removed and excreted as its carnitine conjugate. The elevation in certain acyl 
carnitines may reflect something similar where fatty acids are removed to ensure the functioning of 
glycolysis followed by conversion of pyruvate to acetyl CoA and the oxidation of acetate in the  
Krebs cycle.  
4.6. Steroid Metabolism 
The final major group of metabolites varying between the first post-exercise sample and the other 
samples in the series are urinary steroid metabolites. Urocortisol glucuronide, which is the major 
metabolite of hydrocortisone, was greatly elevated in the first post-exercise sample. Cortisol 
concentration is well known to vary in the blood and its metabolites, urocortisone- 3-glucuronide and 
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urocortisol-3-glucuronide, are downstream metabolites of cortisone and cortisol. The peak times for 
cortisol, cortisone and urocortisone-3-glucronide concentration were found in a study of plasma levels 
to be in the afternoon [45]. This fits with our current observations in urine. However, from the data in 
Table 2, it can be seen that on the non-exercise day, the peak level was in the morning (only 50% of the 
peak level in the first post-exercise sample), and the afternoon samples were still lower. Thus, it would 
appear that exercise does influence the level of hydrocortisone metabolites. This is perhaps not 
surprising, since hydrocortisone is involved in many physiological functions relating to energy 
consumption. For instance, it has been found that corticosteroids can directly promote nitric oxide 
production [46]. There have been previous reports of cortisol metabolism being changed by  
exercise [47,48]. In addition to hydrocortisone metabolism, testosterone metabolism was also affected 
by exercise, and three androgen metabolites were elevated in the first post-exercise sample. There are 
numerous reports that testosterone is elevated in males following exercise [49].  
5. Conclusions 
There have been longitudinal studies looking at the collection of individual urine samples  
over time in normal subjects following exercise. By collecting 24-h pooled urine samples, a lot of 
interesting information could be lost. The metabolic changes we observed in the current pilot  
study have been observed across several papers, although they have not been reported in one single  
study [5,21±29,41,42,47±51]. It is vital, given the profound effects of exercise, that future  
metabolomics-based investigations also take into consideration the impact exercise has on the 
metabolome. For instance comparing a relatively sedentary patient cohort with a more active control 
group would highlight the metabolite changes due to exercise rather than changes due to disease. Another 
pertinent example is the carnitines, which are widely reported as disease markers [52,53]; however, given 
their response to exercise, differences could easily result from two groups that are not adequately 
matched for physical activity. Similarly, purines have been proposed as markers for various types of 
cancer [54], and it is obvious that normalising against creatinine would not compensate for the large 
fluctuations in this pathway due to physical activity. It is evident from the current study that creatinine 
may fluctuate over time with a similar pattern to numerous metabolites; however, it does not necessarily 
do so to the same degree. We therefore recommend that the most robust technique for normalisation 
would be to calculate subject-specific area percentages. This technique does not seem to remove any of 
the abundant features across the subjects, but merely acts to re-stabilise an already variant dataset, the 
latter considered as a norm in metabolomics investigations. In addition, it does not introduce large 
numbers of significant metabolites, but focuses the metabolites affected by exercise into distinct 
pathways, which have all been described before in various papers, ultimately adding increased weight 
to the observations.  
The data obtained from this simple study are extensive, and it would be possible to carry out further 
analysis to uncover further insights into human metabolic fluctuations. However, this will be better done 
on a larger sample size with better control over the dose of exercise administered. The purpose of the 
current study was to demonstrate the underappreciated impact of exercise when carrying out 
metabolomics studies and that continuous collection of all samples from individuals enables us to gain 
some confidence in normalising each metabolite to its total output. The current study, in fact, arose out 
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of the difficulties we experienced when trying to collaborate in a study investigating the effects of 
recombinant human erythropoietin in the spot urine and plasma samples of endurance trained males 
taken over 10 weeks [55]. Although we expected to see an impact on the metabolome, the metabolite 
data were thoroughly stochastic. There was no particular information in the literature that we could turn 
to on this, since few studies have been conducted over such a long period. Thus, we hypothesised that, 
since the individuals concerned were pursuing individual training regimens, the large fluctuations in the 
metabolites we were observing must be due to exercise masking any other effects. Therefore, the current 
study supports this view and also could explain why in metabolomics studies of humans it is often 
difficult to find differences in cohort comparisons, since the physical activity level for an individual is 
not something that is often normalised. It might be possible to normalise for this using a metabolite, such 
as hypoxanthine or a combination of the purine markers, that is greatly affected by exercise, but this 
remains to be studied. The effects of exercise on the metabolome have been recently reviewed [56]. 
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